The one-time gene therapy treatment is priced at $2.1 million and is designed to treat spinal muscular atrophy in infants.
Novartis said about 200 patients have been treated with Zolgensma since it launched last June, according to STAT.
The drug is covered for 97 percent of patients with commercial plans; 50 percent of Medicaid patients are covered.
Read the full article here.
More articles on pharmacy:
Drug shortages update: 5 things to know
Grocery store pharmacies across the country finding it harder to stay in business
AbbVie to donate $1M of drug China says will combat coronavirus
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
